Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

An international workshop, under the auspices of Group d'Etude des Lymphomes de l'Adulte
(GELA) took place in Deauville, France, in April 3–4, 2009. The European experts with a …

Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in …

Background We tested interim positron-emission tomography–computed tomography (PET-
CT) as a measure of early response to chemotherapy in order to guide treatment for patients …

Purpose Patients who receive combined modality treatment for stage I and II Hodgkin
lymphoma (HL) have an excellent outcome. Early response evaluation with positron …

Background Whether it is possible to reduce the intensity of treatment in early (stage I or II)
Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a …

PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …

Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated …

Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin …

Background The intensity of chemotherapy and need for additional radiotherapy in patients
with advanced stage Hodgkin's lymphoma has been unclear. We did a prospective …